Readjudication

$title =

angiopoietin-like 3 gene (ANGPTL3)

;

$content = [

Negative regulator of Lipoprotein Lipase

evinacumab – Regeneron (REGN)

Evidence:

loss-of-function variants in ANGPTL3 with lipid levels and with coronary artery disease in 13,102 case patients and 40,430 controls from the DiscovEHR study

significantly lower serum levels of triglycerides, HDL cholesterol, and LDL cholesterol than participants without these variants.

Prevalence: 0.33% in CAD and 0.45% in controls

(adjusted odds ratio, 0.59; 95% confidence interval, 0.41 to 0.85; P=0.004)

Pharmacotherapy

evinacumab – tesdted in mice

decrease in atherosclerotic lesions

human trial – fasting triglyceride levels of up to 76% and LDL cholesterol levels of up to 23%.

];

$date =

;

$category =

;

$author =

Anthony Taylor

;

$previous =

;

$next =

;